ADCYAP1 and migraine disorder: A centrally, but not peripherally, administered PAC1 receptor antagonist was able to inhibit dural nociceptive-evoked action potentials in central trigeminovascular neurons in rats, suggesting that the central PAC1 receptor is involved in PACAP-induced migraine [143].